Trial reportPLoS pathogens2013
HIV-1 superinfection occurs less frequently than initial infection in a cohort of high-risk Kenyan women.
Trial report in PLoS pathogens, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 47 citations in OpenAlex.
- Dynamics of HIV DNA reservoir seeding in a cohort of superinfected Kenyan women.PLoS pathogens · 2020Trial
- Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation.AIDS (London, England) · 2016Trial
- Randomized Trial of Periodic Presumptive Treatment With High-Dose Intravaginal Metronidazole and Miconazole to Prevent Vaginal Infections in HIV-negative Women.The Journal of infectious diseases · 2015Trial
- Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.The Journal of infectious diseases · 2015Trial
- Limited HIV-1 superinfection in seroconverters from the CAPRISA 004 Microbicide Trial.Journal of clinical microbiology · 2014Trial
- Broadly neutralizing antibody responses in a Chinese acute HIV-1 infection cohort of men who have sex with men.PLoS pathogens · 2026Article
- Quantifying prevalence and risk factors of HIV multiple infection in Uganda from population-based deep-sequence data.PLoS pathogens · 2025Article
- Multiple Infection and Human Immunodeficiency Virus Superinfection Among Persons who Inject Drugs in Indonesia and Ukraine.The Journal of infectious diseases · 2022Article
- Human Immunodeficiency Virus (HIV) Drug Resistance, Phylogenetic Analysis, and Superinfection Among Men Who Have Sex with Men and Transgender Women in Sub-Saharan Africa: HIV Prevention Trials Network (HPTN) 075 Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Article
- Understanding protection from SARS-CoV-2 by studying reinfection.Nature medicine · 2020Article
- Vaccine Design Informed by Virus-Induced Immunity.Viral immunology · 2020Review
- How Basic Immunological Principles May Instruct the Design of a Successful HIV-Type 1 Vaccine.Viral immunology · 2020Article
- Chikungunya virus superinfection exclusion is mediated by a block in viral replication and does not rely on non-structural protein 2.PloS one · 2020Article
- Limited anti-HIV neutralizing antibody breadth and potency before and after HIV superinfection in Danish men who have sex with men.Infectious diseases (London, England) · 2019Article
- Characterization of the Neutralizing Antibody Response in a Case of Genetically Linked HIV Superinfection.The Journal of infectious diseases · 2018Article
- Model-based estimation of superinfection prevalence from limited datasets.Journal of the Royal Society, Interface · 2018Article
- Immunological and virological characteristics of human immunodeficiency virus type 1 superinfection: implications in vaccine design.Frontiers of medicine · 2017Review
- Article
- Increased HIV-1 superinfection risk in carriers of specific human leukocyte antigen alleles.AIDS (London, England) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
HIV superinfection (reinfection) has been reported in several settings, but no study has been designed and powered to rigorously compare its incidence to that of initial infection. Determining whether HIV infection reduces the risk of superinfection is critical to understanding whether an immune response to natural HIV infection is protective. This study compares the incidence of initial infection and superinfection in a prospective seroincident cohort of high-risk women in Mombasa, Kenya. A next-generation sequencing-based pipeline was developed to screen 129 women for superinfection. Longitudinal plasma samples at <6 months, >2 years and one intervening time after initial HIV infection were analyzed. Amplicons in three genome regions were sequenced and a median of 901 sequences obtained per gene per timepoint. Phylogenetic evidence of polyphyly, confirmed by pairwise distance analysis, defined superinfection. Superinfection timing was determined by sequencing virus from intervening timepoints. These data were combined with published data from 17 additional women in the same cohort, totaling 146 women screened. Twenty-one cases of superinfection were identified for an estimated incidence rate of 2.61 per 100 person-years (pys). The incidence rate of initial infection among 1910 women in the same cohort was 5.75 per 100 pys. Andersen-Gill proportional hazards models were used to compare incidences, adjusting for covariates known to influence HIV susceptibility in this cohort. Superinfection incidence was significantly lower than initial infection incidence, with a hazard ratio of 0.47 (CI 0.29-0.75, p = 0.0019). This lower incidence of superinfection was only observed >6 months after initial infection. This is the first adequately powered study to report that HIV infection reduces the risk of reinfection, raising the possibility that immune responses to natural infection are partially protective. The observation that superinfection risk changes with time implies a window of protection that coincides with the maturation of HIV-specific immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.